WO2000042434A1 - Method and device for determining an analyte - Google Patents
Method and device for determining an analyte Download PDFInfo
- Publication number
- WO2000042434A1 WO2000042434A1 PCT/EP2000/000076 EP0000076W WO0042434A1 WO 2000042434 A1 WO2000042434 A1 WO 2000042434A1 EP 0000076 W EP0000076 W EP 0000076W WO 0042434 A1 WO0042434 A1 WO 0042434A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analyte
- zones
- test strip
- capacity
- zone
- Prior art date
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 32
- 230000027455 binding Effects 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 17
- 102100032752 C-reactive protein Human genes 0.000 claims description 17
- 238000003556 assay Methods 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 102000013394 Troponin I Human genes 0.000 claims description 8
- 108010065729 Troponin I Proteins 0.000 claims description 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 8
- 102000036675 Myoglobin Human genes 0.000 claims description 6
- 108010062374 Myoglobin Proteins 0.000 claims description 6
- 239000000020 Nitrocellulose Substances 0.000 claims description 6
- 239000003365 glass fiber Substances 0.000 claims description 6
- 229920001220 nitrocellulos Polymers 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 4
- 229940025084 amphetamine Drugs 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 229960003920 cocaine Drugs 0.000 claims description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002069 diamorphine Drugs 0.000 claims description 4
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- 239000005046 Chlorosilane Substances 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 3
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical class Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 claims description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 3
- 239000004816 latex Substances 0.000 claims description 3
- 229920000126 latex Polymers 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- PWEBUXCTKOWPCW-UHFFFAOYSA-N squaric acid Chemical class OC1=C(O)C(=O)C1=O PWEBUXCTKOWPCW-UHFFFAOYSA-N 0.000 claims description 3
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims description 2
- 241000228197 Aspergillus flavus Species 0.000 claims description 2
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 2
- PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 claims description 2
- PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000009871 nonspecific binding Effects 0.000 claims description 2
- CEOCDNVZRAIOQZ-UHFFFAOYSA-N pentachlorobenzene Chemical compound ClC1=CC(Cl)=C(Cl)C(Cl)=C1Cl CEOCDNVZRAIOQZ-UHFFFAOYSA-N 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000004040 coloring Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003891 environmental analysis Methods 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012206 semi-quantitative assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- the present invention relates to a method for the differential determination of an amount of at least one analyte in a sample using a solid phase and an apparatus for carrying out the method.
- Test strips are often used in today's analytics. Test strips that meet the requirements of a rapid test are essentially based on the principle that a reagent is fixed on a solid matrix that reacts with the analyte to be detected. Under certain circumstances, a color change, a color change or another detectable property can be measured in a subsequent reaction. For example, staining serves as evidence of the presence of an agent to be identified.
- WO-A-98/22824 relates to a so-called inhibitor assay.
- This assay configuration is based on labeled compounds that correspond to or are identical to the analyte.
- the marked compound is placed on the test strip and competes with the analyte present in a sample.
- the marked connection leaves the original zone and can be verified.
- a linear procedure is fundamentally not possible.
- US-A-5,527,509 relates to an assay which determines the analyte by means of enzyme conversion of a low molecular weight analyte and subsequent color reaction. So-called capture assays, which are the subject of the present invention, are not mentioned there. A linear design of this assay is not possible.
- US-A-5,252,496 relates to a color formation process. Basically, only qualitative assays are disclosed there. If the assay is carried out with two zones, one zone serves only as a control.
- US-A-5,229,073 relates to a non-linear competitive immunoassay.
- WO-A-98/36278 relates to a capture immunoassay which has different detection zones with capture components (capture reagents), each of which differ in the capture concentration, so that a linear execution of the assay described there is not possible.
- test strips or similar systems What is common to many test strips or similar systems is that often only one type of staining takes place, so that such a test cannot be quantified. It only serves to determine one Yes / No statement. Either the analyte is present in a detectable amount, which is reflected in the formation of a color, or there is no coloring, so that the analyte does not exceed a previously determined limit value, that is to say it is below the detection limit of the respective test strip or test system. In order to be able to switch off systematic errors, a function check must also be provided by introducing a further reaction-independent parameter. This structure of test strips is sufficient for many applications. However, questions such as the severity of a stress or illness or change in the amount of an analyte during a rehabilitation process or a therapy attempt cannot be answered satisfactorily.
- the technical problem underlying the invention therefore consists in avoiding the above-mentioned disadvantages of the systems already present in the prior art and in providing quantifying rapid tests.
- the problem on which the invention is based is solved by a method for the differential determination of an amount of at least one analyte in a liquid sample using a test strip.
- Differential determination is understood to mean an at least semi-quantitative determination, that is to say an analysis going beyond a purely qualitative determination.
- This test strip must have at least two zones and ensure a lateral flow of the liquid sample or a portion of the sample through the test strip and the at least two zones.
- At least two zones are designed in such a way that they are able to make a statement about the amount of the at least one analyte, in that a first zone has a predefined capacity for binding the at least one analyte and if this capacity is exceeded, by the amount of the at least one analyte which is too large for this capacity, the at least one analyte is bound in at least one second zone, the capacity of the at least two zones being essentially the same in each case and the binding of the at least one analyte in the at least first and at least one second zone is measured by a detectable property.
- the amount of the at least one analyte is preferably determined by an activity of the at least one analyte.
- the analyte can be bound specifically and / or non-specifically on the test strip.
- the specific binding of the at least one analyte preferably takes place via an affinity for another ligand or affinity for the material used for the test strip.
- binding via immunoaffinity by binding partners bound specifically or unspecifically to the surface of the test strip is possible.
- An example of the non-specific binding of the at least one analyte on the Test strip is the precipitation of the at least one analyte on the test strip used.
- the specific binding between the at least one analyte and an affinity binding partner comes, for example, through receptor / ligand interaction, enzyme / substrate interaction, antigen / antibody interaction and other affinity binding, such as avidin, streptavidin, protein A, IgG and others known to the person skilled in the art Systems, established.
- the defined capacity for binding the at least one analyte on the test strip is determined as a function of the amount of the at least one analyte to be expected in a sample to be analyzed, in order to at least exceed the capacity of the at least first zone to be able to detect an analyte in the second zone.
- the difference in capacity of the capture component applied in the capture and assay according to the invention in the first and second zones is preferably not more than + 10%, in particular + 5%. It should generally be noted that the more precisely the capacity of the catcher can be set in the at least two zones, the more precisely the linearity of the assay according to the invention is. If more than two zones are used, it can be advantageous to provide the zone beyond that with a higher amount of catcher, that is to say to increase the capacity of this zone in order to achieve better detection. When using several zones, the last zone is preferably provided with a higher capacity of the catcher.
- the advantage of the present invention is to be seen in the fact that essentially equal amounts of binding agent (scavenger) are applied.
- FIG. 1 explains the method of operation of the method according to the invention by way of example.
- FIG. 2 shows a result of the method according to the invention if three zones, each with a defined capacity, are provided.
- FIG. 3 relates to a device with the test strip according to FIG. 4.
- FIG. 4 relates to the test strip according to the invention.
- FIG. 1 shows schematically the fixation of an antibody on a solid matrix, for example nitrocellulose.
- the phase coated in lb) is then treated with the analyte.
- the analyte binds to the corresponding antibody via immunoaffinity.
- This is then added to the detection in 1 c, for example with a further antibody which binds to the antigen and is in turn labeled, in particular by a gold colloid. This indicates the presence of the analyte.
- Enough capacity of the first If the zone is not sufficient to bind all analytes in the sample, these diffuse further with other sample components on the solid porous support in the direction of the at least second zone, in which the analytes are then bound by the antibodies immobilized there.
- an analyte it is therefore possible to differentiate whether amounts of an analyte are present in a sample below the detection limit, above the detection limit or significantly above the detection limit.
- the maximum bindable amount of analyte is thus bound in the first zone and if the amount of analyte present is exceeded, further binding will take place in the at least second zone or further zones.
- an analysis target can be processed in a variety of ways.
- the number of zones By increasing the number of zones, a fine division of the measuring range to be recorded can be achieved. For practical reasons, however, the number of zones will regularly be between three and ten. The upper limit will be determined regularly by the readability or interpretability of the results.
- Figure 2 shows the example of a medical immunoassay.
- the amount of C-reactive proteins bound in plasma is approximately between 0.2 and 200 mg / 1, values up to approximately 10 mg / 1 being considered normal. Concentrations above this value indicate different forms of bacterial infections.
- the plasma concentration of C-reactive proteins reacts very quickly to positive treatment, in practice all concentrations actually occur in the range mentioned.
- the situation shown schematically in FIG. 2 now shows three different zones which can interact immunologically with C-reactive proteins.
- the following three are regular Read conditions visually: - no coloring, (+) weak and + intensive coloring. If the situation shown in FIG. 2 as situation 1, namely weak coloring in the first zone and no coloring in the second and third zones, is shown in a test strip, the amount of C-reactive protein is in the range from 0.2 to 5 mg /1. The capacity of the respective zones was matched to these quantities.
- Situation 2 now shows an increased plasma concentration of C-reactive protein in that the staining is correspondingly more intense.
- This situation corresponds to a content of 5 to 10 mg / 1
- situation 3 the maximum possible coloration is formed in the first zone and a weaker coloration in the second zone, whereas zone 3 is not colored at all, which indicates an amount of 11 to 15 mg / 1 indicates
- situation 4 shows strong coloring in the first and second zones
- the third zone is not colored, which corresponds to a plasma level of 16 to 25 mg / 1
- situation 5 shows maximum coloring in and in the first two zones
- Zone 3 weak staining corresponding to a plasma level of 25 to 50 mg / 1
- situation 6 shows strong staining in all three areas, from which it can then be concluded that> 50 mg / 1 is present.
- This three-zone model given by way of example therefore allows a six-stage differentiation by simply combining the number of colored zones and the intensity of dyeing.
- the first zone With a capacity between 0.2 and 5 mg / 1, a functional control is also inherently available, since the first zone must be weakly positive in practically every patient (basal level).
- analyte C-reactive protein CRP
- rheumatoid factors CRP
- troponin I troponin I
- creatinine kinase CK-MB
- myoglobin antigens of the organisms Samonella, Legionella, E. coli (EHEC), Aspergillus flavus and fumigatus, glucose, Dioxin, PCB, cocaine (ecgonine), heroin, amphetamine and other pathologically indicative or environmentally relevant substances
- ECP C-reactive protein
- CK-MB creatinine kinase
- myoglobin antigens of the organisms Samonella, Legionella, E. coli (EHEC), Aspergillus flavus and fumigatus
- glucose, Dioxin PCB
- cocaine ecgonine
- heroin amphetamine and other pathologically indicative or environmentally relevant substances
- two or more analytes can advantageously also be determined in parallel.
- the following pairs come into consideration as analytes that can be determined in pairs with clinical or environmental analytical relevance: CRP and antistreptolysin, troponin I and CK-MB, myoglobin and CK-MB, CK-MB, myoglobin and troponin I, cocaine, heroin and amphetamine , Samonella and E. coli.
- a material that has a certain porosity is in principle possible, such as porous supports comprising nitrocellulose, nylon, PTFE, polystyrene, latex, glass fibers, silica gel, aluminum oxide, cellulose, dextran, agarose , Polyvinyl alcohol, also as microspheres or "magnetobeads", optionally preactivated with BrCN, NPCF, NHS chloroformate, tresyl chloride, squaric acid esters and / or corresponding chlorosilanes.
- porous supports comprising nitrocellulose, nylon, PTFE, polystyrene, latex, glass fibers, silica gel, aluminum oxide, cellulose, dextran, agarose , Polyvinyl alcohol, also as microspheres or "magnetobeads", optionally preactivated with BrCN, NPCF, NHS chloroformate, tresyl chloride, squaric acid esters and / or corresponding chlorosilanes.
- the method according to the invention is therefore particularly user-friendly since individual analytical problems can be solved by selecting the concentrations which are to be detected in the individual zones. For example, the user himself, e.g. B. by covering the zones with one with the analyte in Interacting agent to tackle individual analysis problems.
- the test strip according to the invention which is suitable for carrying out the method according to the invention has an essentially porous carrier 2 which can be penetrated by liquids and at least two zones 3, 4 with at least one catcher for at least one analyte, the at least one analyte directly or indirectly to the Captor is bound and the zones 3, 4 each have a previously defined binding capacity for the at least one analyte, which is essentially the same and the catchers are the same for the respective analytes.
- a typical test strip is shown in Figure 4.
- the device according to the invention for carrying out the method according to the invention receives the test strip according to the invention.
- the device has a housing in which the test strip is arranged.
- the housing consists of an upper side which has at least one opening at the locations of the at least two zones of the test strip, which extends over the region of the at least two zones of the test strip and at least one further opening for application of at least one sample and / or auxiliary substances to be examined for performing an assay that allows contact of a liquid with the test strip.
- the device preferably has a further opening for receiving auxiliary reagents.
- the device instead of the one opening 12 which extends over the entire area of zones 3, 4 of the test strip, it has as many openings as corresponds to the number of zones of the test strip. To read the result in the zones of the test strip, it is necessary that the openings in the housing are essentially congruent with the zones of the test strip.
- FIG. 3 shows a preferred embodiment of the device according to the invention.
- an opening 12 is provided which extends over the area of the at least two zones 3, 4 of the test strip 1.
- an opening 14 is provided, with the aid of which the sample to be examined is applied. If necessary, auxiliaries for carrying out the method according to the invention can also be added through the opening 14.
- the opening 14 has a wall and is connected to the test strip 1. After application of the sample, this pulls into the test strip due to the porosity of the test strip and, due to capillary forces, migrates in a lateral direction through the test strip and therefore through zones 3, 4.
- the size of the opening 14 determines the volume that the opening can accommodate. The sample volume is precisely determined by the exact diameter and the height of the opening.
- the sample receiving volume is increased by means of a tube which can be inserted into the opening. It is in particular possible to provide a defined volume by inserting a tube with a defined volume (defined wall thickness and length), which is matched to the quantitative or semi-quantitative assay that can be carried out with the device according to the invention.
- the further opening 15 is suitable for receiving auxiliary reagents.
- the opening 14 can be adapted to the respective needs by further additions. Is z. B. directly under the opening 14 in contact with the test strip, a commercially available membrane that is able to separate blood cells from plasma through its defined pore opening, an analysis of plasma parameters can be carried out directly in the test strip.
- This membrane can be, for example, a glass fiber filter with a suitable density or a plastic membrane with narrow channels, advantageously with asymmetrical channels that allow blood to penetrate. This fulfills the requirements for a quick test for on-site analysis.
- interference parameters can be selectively filtered out using suitable media. If the opening 14 z. B. filled with aluminum oxide, a sample can be degreased directly, which is of great importance in food analysis. Similarly, particles can be removed by using a filter membrane or soil samples can be examined directly by using a filter together with an absorbent medium (e.g. activated carbon).
- an absorbent medium e.g. activated carbon
- test strip according to the invention can be produced in a manner known per se (WO-A-95/13542).
- test strips can be produced which can be used by the customer himself.
- the zones on the test strip that are to be used for the detection of the analyte are only preactivated, for example by chemical activation or coating using immunoreactive substances, for example protein A, protein G, streptavidin, etc.
- the user then only needs to modify his analyte with complementary structures or to bind antibodies against the analyte in the zones in order to use the test strip for his purposes.
- the quantitative determination of C-reactive protein is carried out in the following way: the reactive zones 3, 4 and a corresponding third zone are loaded with 2.3 ⁇ g each of an anti-human CRP antibody from rabbits on a 4 cm wide nitrocellu strip. The excess reactive groups of the nitrocellulose are then saturated with skimmed milk. Then a test strip consisting of the nitrocellulose, a porous glass fiber strip for receiving the anti-CRP-gold conjugate and a blood piasma-separating glass fiber membrane are mounted on a self-adhesive plastic film. After the application of thick paper strips to hold the necessary washing liquids, 5 mm wide strips are placed in a housing as shown in Figure 3.
- the opening 14 is filled with 20 ⁇ l of blood (this corresponds reproducibly to an amount of plasma which is suitable for carrying out the test and which reaches the test strip). After 2 minutes, the opening 15 is filled with buffer.
- the plasma is guided over the three reactive zones.
- the buffer first passes through the glass fiber filter with the lyophilized gold-antibody conjugate and from there across the zones to which the CRP has already bound. At the points where CRP is present, the gold conjugate also binds and thus produces a color.
- troponin I and CK-MB can also be measured in parallel in an analogous manner. Both parameters are important indicators of a myocardial infarction, but depending on the cause of the myocardial damage, the amount increases in time, so that their parallel determination provides important diagnostic information.
- two zones are applied with a monoclonal mouse anti-human troponin I or CK-MB antibody.
- the difference to the test according to Example 1 is that lyophilized antibody-enzyme conjugates are used instead of the antibody-gold conjugate. These antibodies are directed against a second domain of the analyte.
- anti-troponin I is conjugated with peroxidase, anti-CK-MB with alkaline phosphatase.
- BCIP / INT a phosphatase reagent which leaves an orange precipitate in the place of the phosphatase
- TMB a peroxidase reagent, blue dye
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00901513A EP1141713A1 (en) | 1999-01-09 | 2000-01-07 | Method and device for determining an analyte |
CA002358506A CA2358506A1 (en) | 1999-01-09 | 2000-01-07 | Method and device for determining an analyte |
AU22882/00A AU2288200A (en) | 1999-01-09 | 2000-01-07 | Method and device for determining an analyte |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99100410 | 1999-01-09 | ||
EP99100410.2 | 1999-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000042434A1 true WO2000042434A1 (en) | 2000-07-20 |
Family
ID=8237329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/000076 WO2000042434A1 (en) | 1999-01-09 | 2000-01-07 | Method and device for determining an analyte |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1141713A1 (en) |
AU (1) | AU2288200A (en) |
CA (1) | CA2358506A1 (en) |
WO (1) | WO2000042434A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1546722A2 (en) * | 2002-06-07 | 2005-06-29 | Cholestech Corporation | Automated immunoassay cassette, apparatus and mehtod |
EP1664296A1 (en) * | 2003-08-28 | 2006-06-07 | Canon Kabushiki Kaisha | Probe carrier and method for quantifying target substance using the probe carrier |
US7238519B2 (en) | 2002-06-07 | 2007-07-03 | Cholestech Corporation | Automated immunoassay cassette, apparatus and method |
US7393697B2 (en) | 2003-06-06 | 2008-07-01 | Advantage Diagnostics Corporation | Diagnostic test for analytes in a sample |
WO2010022543A1 (en) * | 2008-08-29 | 2010-03-04 | 红电医学科技股份有限公司 | Liquid test strip |
US7763433B2 (en) | 2004-07-01 | 2010-07-27 | Forsite Diagnostics Limited | Analyte detection system |
US7795038B2 (en) | 2002-04-09 | 2010-09-14 | Cholestech Corporation | High-density lipoprotein assay device and method |
US7824879B2 (en) | 2007-01-09 | 2010-11-02 | Cholestech Corporation | Device and method for measuring LDL-associated cholesterol |
US7964370B2 (en) | 2008-10-17 | 2011-06-21 | Actherm Inc | Analytical strip and detecting method using the same |
WO2012020122A1 (en) | 2010-08-13 | 2012-02-16 | Dentognostics Gmbh | Process for avoiding false positive results in a detecting process of an inflammation indicator in a rinse solution for taking up gingival crevicular fluid |
EP2419724A2 (en) * | 2009-04-15 | 2012-02-22 | Relia Diagnostic Systems, Inc. | Expanding the dynamic range of a test strip |
US8133718B2 (en) | 2008-10-17 | 2012-03-13 | Actherm Inc | Analytical strip and detecting method using the same |
US8367015B2 (en) | 2009-03-23 | 2013-02-05 | Actherm Inc | Analytical strip and the manufacturing method thereof |
US8372660B2 (en) | 2008-10-09 | 2013-02-12 | Actherm Inc | Quantitative analyzing method |
JP2014528067A (en) * | 2011-09-08 | 2014-10-23 | ネクサス・ディーエックス・インコーポレイテッドNexus Dx, Inc. | Multi-level analyte assay |
CN106290881A (en) * | 2015-06-01 | 2017-01-04 | 上海凯创生物技术有限公司 | Salmonella near-infrared fluorescent method detection kit |
CN118501437A (en) * | 2024-07-18 | 2024-08-16 | 西北师范大学 | Fluorescent lateral flow immunochromatography test strip for detecting CRP in blood plasma |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108254550B (en) * | 2016-12-28 | 2019-10-25 | 广州瑞博奥生物科技有限公司 | Detect time-resolved fluoroimmunoassay chromatograph test strip, the kit and preparation method thereof of CK-MB |
CN108254563B (en) * | 2016-12-28 | 2019-10-29 | 广州瑞博奥生物科技有限公司 | Detect time-resolved fluoroimmunoassay chromatograph test strip, the kit and preparation method thereof of cTnI |
EP4058810A4 (en) * | 2019-11-15 | 2023-12-20 | President And Fellows Of Harvard College | Device and method for analyte detection |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042329A (en) * | 1974-12-18 | 1977-08-16 | Becton, Dickinson And Company | Method and device for detecting cholesterol |
US4059407A (en) * | 1976-04-14 | 1977-11-22 | Becton, Dickinson And Company | Disposable chemical indicators |
US5229073A (en) * | 1992-02-27 | 1993-07-20 | Abbott Laboratories | One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein(a) |
WO1996034271A1 (en) * | 1995-04-27 | 1996-10-31 | Quidel Corporation | One step urine creatinine assays |
WO1996034287A1 (en) * | 1995-04-28 | 1996-10-31 | Quidel Corporation | Assays and devices for distinguishing between normal and abnormal pregnancy |
EP0833159A2 (en) * | 1996-09-25 | 1998-04-01 | Becton, Dickinson and Company | Direct read lateral flow assay for small analytes |
WO1998036278A1 (en) * | 1997-02-15 | 1998-08-20 | Beth Israel Deaconess Medical Center, Inc. | Multiple-site antibody capture immunoassays and kits |
-
2000
- 2000-01-07 CA CA002358506A patent/CA2358506A1/en not_active Abandoned
- 2000-01-07 EP EP00901513A patent/EP1141713A1/en not_active Withdrawn
- 2000-01-07 AU AU22882/00A patent/AU2288200A/en not_active Abandoned
- 2000-01-07 WO PCT/EP2000/000076 patent/WO2000042434A1/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042329A (en) * | 1974-12-18 | 1977-08-16 | Becton, Dickinson And Company | Method and device for detecting cholesterol |
US4059407A (en) * | 1976-04-14 | 1977-11-22 | Becton, Dickinson And Company | Disposable chemical indicators |
US5229073A (en) * | 1992-02-27 | 1993-07-20 | Abbott Laboratories | One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein(a) |
WO1996034271A1 (en) * | 1995-04-27 | 1996-10-31 | Quidel Corporation | One step urine creatinine assays |
WO1996034287A1 (en) * | 1995-04-28 | 1996-10-31 | Quidel Corporation | Assays and devices for distinguishing between normal and abnormal pregnancy |
EP0833159A2 (en) * | 1996-09-25 | 1998-04-01 | Becton, Dickinson and Company | Direct read lateral flow assay for small analytes |
WO1998036278A1 (en) * | 1997-02-15 | 1998-08-20 | Beth Israel Deaconess Medical Center, Inc. | Multiple-site antibody capture immunoassays and kits |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795038B2 (en) | 2002-04-09 | 2010-09-14 | Cholestech Corporation | High-density lipoprotein assay device and method |
EP1546722A2 (en) * | 2002-06-07 | 2005-06-29 | Cholestech Corporation | Automated immunoassay cassette, apparatus and mehtod |
US7220595B2 (en) | 2002-06-07 | 2007-05-22 | Cholestech Corporation | Automated immunoassay cassette, apparatus and method |
US7238519B2 (en) | 2002-06-07 | 2007-07-03 | Cholestech Corporation | Automated immunoassay cassette, apparatus and method |
EP1546722A4 (en) * | 2002-06-07 | 2005-11-02 | Cholestech Corp | Automated immunoassay cassette, apparatus and mehtod |
JP2005529325A (en) * | 2002-06-07 | 2005-09-29 | コレステック コーポレイション | Automated immunoassay cassette, apparatus and method |
US7393697B2 (en) | 2003-06-06 | 2008-07-01 | Advantage Diagnostics Corporation | Diagnostic test for analytes in a sample |
EP1664296A1 (en) * | 2003-08-28 | 2006-06-07 | Canon Kabushiki Kaisha | Probe carrier and method for quantifying target substance using the probe carrier |
EP1664296B1 (en) * | 2003-08-28 | 2015-02-25 | Canon Kabushiki Kaisha | METHOD FOR QUANTIFYING TARGET SUBSTANCE USING a PROBE CARRIER |
US7763433B2 (en) | 2004-07-01 | 2010-07-27 | Forsite Diagnostics Limited | Analyte detection system |
EP2426193A1 (en) * | 2004-12-17 | 2012-03-07 | Cholestech Corporation | Automated immunoassay cassette, apparatus and method |
EP1831345A4 (en) * | 2004-12-17 | 2011-06-22 | Cholestech Corp | Automated immunoassay cassette, apparatus and method |
EP1831345A2 (en) * | 2004-12-17 | 2007-09-12 | Cholestech Corporation | Automated immunoassay cassette, apparatus and method |
US7824879B2 (en) | 2007-01-09 | 2010-11-02 | Cholestech Corporation | Device and method for measuring LDL-associated cholesterol |
WO2010022543A1 (en) * | 2008-08-29 | 2010-03-04 | 红电医学科技股份有限公司 | Liquid test strip |
US8372660B2 (en) | 2008-10-09 | 2013-02-12 | Actherm Inc | Quantitative analyzing method |
US7964370B2 (en) | 2008-10-17 | 2011-06-21 | Actherm Inc | Analytical strip and detecting method using the same |
US8133718B2 (en) | 2008-10-17 | 2012-03-13 | Actherm Inc | Analytical strip and detecting method using the same |
US8367015B2 (en) | 2009-03-23 | 2013-02-05 | Actherm Inc | Analytical strip and the manufacturing method thereof |
EP2419724A4 (en) * | 2009-04-15 | 2012-11-28 | Relia Diagnostic Systems Inc | Expanding the dynamic range of a test strip |
EP2419724A2 (en) * | 2009-04-15 | 2012-02-22 | Relia Diagnostic Systems, Inc. | Expanding the dynamic range of a test strip |
WO2012020122A1 (en) | 2010-08-13 | 2012-02-16 | Dentognostics Gmbh | Process for avoiding false positive results in a detecting process of an inflammation indicator in a rinse solution for taking up gingival crevicular fluid |
JP2014528067A (en) * | 2011-09-08 | 2014-10-23 | ネクサス・ディーエックス・インコーポレイテッドNexus Dx, Inc. | Multi-level analyte assay |
EP2753684A4 (en) * | 2011-09-08 | 2015-08-26 | Nexus Dx Inc | A multilevel analyte assay |
CN106290881A (en) * | 2015-06-01 | 2017-01-04 | 上海凯创生物技术有限公司 | Salmonella near-infrared fluorescent method detection kit |
CN118501437A (en) * | 2024-07-18 | 2024-08-16 | 西北师范大学 | Fluorescent lateral flow immunochromatography test strip for detecting CRP in blood plasma |
Also Published As
Publication number | Publication date |
---|---|
AU2288200A (en) | 2000-08-01 |
CA2358506A1 (en) | 2000-07-20 |
EP1141713A1 (en) | 2001-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000042434A1 (en) | Method and device for determining an analyte | |
DE68922148T2 (en) | Investigation process and device. | |
DE3887771T3 (en) | Immunoassays and devices therefor. | |
DE68911674T2 (en) | TEST PROCEDURE AND REAGENT SET THEREFOR. | |
DE3322373C2 (en) | Test means and methods for the detection of antigens and / or antibodies | |
DE3889833T2 (en) | Diagnostic device and method, characterized by a targeted flow. | |
DE69718558T2 (en) | Method of amplifying the response signal in a sandwich immunoassay | |
DE68920176T2 (en) | Solid phase analytical device and method of using the same. | |
DE3781335T2 (en) | IMMUNOASSAY WITH THE USE OF COLLOIDAL GOLD. | |
DE3879048T2 (en) | DEVICE FOR LATERAL IMMUNOCHROMATOGRAPHIC DETERMINATION. | |
DE69921199T2 (en) | TWO DIRECTIONAL FLUX TEST STRIPS AND METHOD | |
DE602004013147T2 (en) | NATIVE ANALYTES AS REFERENCE IN LATERAL FLOW ASSAYS | |
DE3872621T2 (en) | DETECTION OF SURROUNDING CONCENTRATIONS OF SEVERAL ANALYZES. | |
DE69329377T2 (en) | RELEASE AGENT FOR RED BLOOD CELLS IN EXAMINATIONS WITH SPECIFIC BINDING | |
DE69131933T2 (en) | Test device for ligand-receptor methods | |
EP1759209B1 (en) | Method for increasing the dynamic measuring range of test elements, especially immunological test elements, that are based on specific bonding reactions | |
DE3786388T2 (en) | Analytical device and method for the detection of Chlamydia Trachomatis and Neisseria Gonorrhoeae. | |
DE69231362T2 (en) | SIMULTANEOUS TESTING OF MEDICINAL PRODUCTS AND FINGERPRINT TEST PROCEDURE | |
EP0998675A1 (en) | Use of check surfaces for identifying disturbing samples in a detection procedure | |
DE68909568T2 (en) | Analytical test device. | |
EP0407904B1 (en) | Method for the determination of an analyte | |
DE60117699T2 (en) | ANALYSIS PROCEDURE BY SPECIFIC BINDING AND DEVICE THAT USES THE PROCESS | |
EP1808696A1 (en) | Immunological test element with improved control zone | |
CH627280A5 (en) | ||
DE212013000068U1 (en) | Apparatus for determining at least one analyte which may be contained in a liquid sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2358506 Country of ref document: CA Ref country code: CA Ref document number: 2358506 Kind code of ref document: A Format of ref document f/p: F |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000901513 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09869906 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000901513 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000901513 Country of ref document: EP |